Article Text

Download PDFPDF

P-009 EmboTrap extraction and clot evaluation and lesion evaluation for neurothrombectomy: methods for the EXCELLENT registry
  1. A Siddiqui1,
  2. T Andersson2,
  3. S De Meyer3,
  4. K Doyle4,
  5. J Fiehler5,
  6. W Hacke6,
  7. R Hanel7,
  8. T Jovin8,
  9. D Kallmes9,
  10. D Liebeskind10,
  11. A Yoo11,
  12. O Zaidat12,
  13. R Nogueria13
  1. 1Neurosurgery, State University of New York at Buffalo, Buffalo, NY
  2. 2Neuroradiology, Karolinska Institute, Stockholm, Sweden
  3. 3Laboratory for Thrombosis Research, KU Leuven, Campus Kulak Kortrijk, Kortrijk, Belgium
  4. 4Physiology, National University of Ireland, Galway, Galway, Ireland
  5. 5Neurosurgery, University Medical Center Hamburg, Hamburg, Germany
  6. 6Neurology, University of Heidelberg, Heidelberg, Germany
  7. 7Neurosurgery, Baptist Stroke and Cerebrovascular Center, Jacksonville, FL
  8. 8Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA
  9. 9Radiology, Mayo Clinic, Rochester, MN
  10. 10Neurology, University of California Los Angeles, Los Angeles, CA
  11. 11Interventional Radiology, Texas Stroke Institute Dallas-Fort Worth, Buffalo, NY
  12. 12Mercy St Vincent Medical Center, Toledo, OH
  13. 13Neurosurgery, Emory University School of Medicine, Atlanta, GA


Rationale The EmboTrap Revascularization Device has been shown to be effective in achieving successful reperfusion in emergent large vessel occlusion (ELVO) patients, with clinical outcomes comparable to existing stent retriever devices. Prospective multicenter data on the real-world experience with EmboTrap is not available.

Aim The primary objective of the study is to assess the efficacy of routine, real-world experience of the EmboTrap and to explore the associations between imaging characteristics at presentation, including volume of core and penumbra, final infarct volume, histologic clot characteristics, subject comorbidities, revascularization rate, and clinical outcomes.

Design This is a prospective, global, multi-center, single-arm, observational registry. Up to 1000 subjects at 50 different sites in Europe and US may be enrolled in the study.

Adult patients (>18 years) with angiographically confirmed ELVO, and treated with EmboTrap as first attempted device will be eligible for participation in the study. Patients with confirmed pregnancy or enrolled in another investigational clinical trial will be excluded.

This study will utilize expanded thrombolysis in cerebral infarction score (eTICI) and an independent Core Imaging Laboratory to assess baseline CT/MR imaging (e.g. ASPECTS, infarct volume, clot location, perfusion), procedural angiography (eTICI score for every pass, emboli to new territories, collateral score) and post-procedure CT/MR imaging (infarct volume, intracranial hemorrhage). All imaging will be read independently by an experienced Imaging Core Lab blinded to all clinical data. In addition, an independent Core Laboratory will also perform clot analysis.

Study outcomes Pre-specified endpoints of the study include successful revascularization (modified thrombolysis in cerebral infarction score ≥ 2b), first pass effect (eTICI ≥ 2c in a single pass without rescue), number of passes, functional independence assessed as modified Rankin Score of ≤ 2 at 90 days, 2 rates of embolization to new territory, symptomatic intracranial hemorrhage at 24 hours and all-cause mortality at 90 days.

Analysis Standard descriptive statistical summaries will be provided. For categorical endpoints, two-sided exact 95% confidence intervals will be presented. Regression analyses will be conducted to determine the association between baseline subject comorbidities, clot characteristics and reperfusion, with a focus on imaging findings. The plan for per pass analysis both by an independent core imaging laboratory and by an independent clot analysis laboratory sets apart this registry from other similar studies. In addition, the reperfusion assessment by the independent core lab will be using innovative eTICI.

Disclosures A. Siddiqui: 1; C; Co-investigator NIH/NINDS 1R01NS091075. 2; C; Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA Inc, Cerebrotech Medical Systems, Cerenovus, Corindus Inc., Endostream Medical Ltd, Guidepoint Global Consulting, Imperative Care, Integra LifeSciences Corp, Medtronic, MicroVention, Q’Apel Medical Inc, Rapid Medical, Rebound Therapeutics Corp., Serenity Medical Inc, Silk Road Medical, StimMed, Stryker, Three Rivers Medical, VasSol, W.L. Gore & Associates. 4; C; Amnis Therapeutics, Apama Medical, Blink TBI Inc, Buffalo Technology Partners Inc, Cardinal Consultants, Cerebrotech Medical Systems, Cognition Medical, Endostream Medical Ltd, Imperative Care, International Medical Distribution Partners, Neurovascular Diagnostics Inc, Q’Apel Medical Inc, Rebound Therapeutics Corp, Rist Neurovascular In, Serenity Medical, Silk Road Medical, StimMed, Synchron, Three Rivers Medical Inc, Viseon Spine. T. Andersson: 2; C; Neuravi, Ablynx, Amnis Therapeutics, Medtronic, Rapid Medical, Stryker. S. De Meyer: None. K. Doyle: None. J. Fiehler: None. W. Hacke: None. R. Hanel: 2; C; Three Rivers Medical, Medtronic, Microvention, Codman, Stryker. T. Jovin: 2; C; Neuravi, codman, Medtronic, Stryker, Silk Road, Anaconda, Blockade Medical. D. Kallmes: None. D. Liebeskind: None. A. Yoo: 2; C; Cerenovus. O. Zaidat: 2; C; Stryker, Medtronic, Neuravi, Penumbra. R. Nogueria: 2; C; Neuravi, Medtronic, Penumbra, Stryker.

  • EmboTrap Revascularization Device
  • Large Vessel Occlusion
  • modified Rankin Score
  • mechanical thrombectomy
  • thrombolysis in cerebral infarct score

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.